Drug intelligence / Profile preview

PSV Personalized Oncolytic Viruses

Development stage: Preclinical
Lead developer: EpicentRx
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral, Subcutaneous

Overview

PSV Personalized Oncolytic Viruses is an oncolytic virus therapy developed by EpicentRx, Inc. It is designed to selectively infect and replicate within cancer cells, leading to their destruction (oncolysis). Beyond direct tumor cell killing, PSV also stimulates a robust anti-tumor immune response by releasing tumor antigens and danger signals, effectively acting as an in situ vaccine. This dual mechanism aims to eliminate cancer cells and prime the immune system to target remaining tumor cells. It is being investigated for patients with advanced cancers who have exhausted standard treatments like chemotherapy and immunotherapy.

Other names: Personalized Virus

Beyond the preview

Go deeper on PSV Personalized Oncolytic Viruses.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSV Personalized Oncolytic Viruses.

Explore the full profile